Tolerability and clinical efficacy of oral immunotherapy with house dust mites in a model of canine atopic dermatitis: a pilot study.
Atopic dermatitis (AD) is a chronic, life-long disease. In humans, immunotherapy (IT) is the only treatment that can alter the course of AD. Oral IT is appealing owing to the ease of administration and the potential for increased compliance. The purposes of this study were to investigate the tolerability, clinical efficacy and effects on allergen-specific IgE of oral IT using a canine AD model. Thirteen atopic beagles sensitized to house dust mites (HDMs) were randomly divided into two groups. One group received daily oral doses of HDMs while the other group received vehicle only for 7 months. The investigator evaluating the dogs was blinded to the allocation of treatments. Prior to and after 2 and 7 months of IT, dogs were challenged daily with HDMs for 3 days concurrently, and clinical signs were scored using a modified Canine Atopic Dermatitis Extent and Severity Index (CADESI). Prior to and at completion of oral IT, serum was collected for measurement of allergen-specific IgE. Oral IT was well tolerated, and no adverse effects were noted. Analysis of variance showed no significant effect of time, group and group × time interaction for CADESI scores. In addition, there were no significant differences in allergen-specific IgE levels. In conclusion, it appears that oral administration of HDMs is well tolerated in these atopic beagles but that this protocol was not sufficient to induce clinical improvement. Further, longer-term studies will be necessary to explore the potential of oral IT in veterinary medicine.
Marsella
Rosanna
R
University of Florida, College of Veterinary Medicine, Gainesville, FL 32610-0126, USA. marsellar@vetmed.ufl.edu
D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000818:Animals; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000276:immunology; D004285:Dogs; D005260:Female; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D008297:Male; D010865:Pilot Projects; D039981:Pyroglyphidae / Q000276:immunology*; D016896:Treatment Outcome
D000485:Allergens; D007073:Immunoglobulin E